Savara Inc. Securities Lawsuit Investigation

Shamis & Gentile P.A., one of the nation's premier class action law firms specializing in securities fraud cases, is investigating potential claims against Savara Inc. (SVRA).

If you purchased or held Savara Inc. securities between March 07, 2024 and May 23, 2025, you may be eligible to join this class action lawsuit and seek compensation for your losses.

About Savara Inc.

Savara Inc. (NASDAQ: SVRA) is a clinical-stage biopharmaceutical company based in Langhorne, Pennsylvania. Founded in 2007, Savara focuses on developing therapies for rare respiratory diseases. The company’s lead product candidate is MOLBREEVI (molgramostim), an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) intended for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disorder.

The Allegations

The lawsuit alleges that Savara Inc. and certain executives made false and/or misleading statements, or failed to disclose important information, about the company’s regulatory filings and financial outlook during the class period of March 07, 2024 to May 23, 2025.

Is alleged that:

• The Biologics License Application (BLA) for MOLBREEVI lacked sufficient information regarding chemistry, manufacturing, and controls (CMC).
• The FDA was unlikely to approve the BLA in its submitted form.
• Savara was unlikely to complete its submission within the timeframe represented to investors.
• The delay in regulatory approval increased the likelihood that Savara would need to raise additional capital.

On May 27, 2025, Savara announced it had received a Refusal to File (RTF) letter from the FDA for the MOLBREEVI BLA, with the agency requesting additional CMC data. This news led to a sharp decline in Savara’s stock price, which fell by approximately 31.69%, down from $2.84 per share on May 23, 2025 to $1.94 per share on May 27, 2025.

The complaint, filed on September 8th in the United States District Court for the Eastern District of Pennsylvania, seeks to recover damages for investors who suffered losses as a result of the alleged misconduct.

Important Dates

• Class period: March 07, 2024 to May 23, 2025
• Lead plaintiff deadline: November 07, 2025
• Complaint filed: September 08, 2025

Your Rights and Next Steps

If you purchased or otherwise acquired Savara Inc. securities during the class period, you may have the right to participate in the class action lawsuit as a lead plaintiff or class member. The lead plaintiff is typically the investor with the largest financial interest in the relief sought by the class and is responsible for directing the litigation on behalf of all class members.

To protect your rights, it is important to act before the lead plaintiff deadline of November 07, 2025. Even if you decide not to serve as a lead plaintiff, you may still be eligible to share in any potential recovery if the lawsuit is successful.

Lawyers are ready to help you understand your options, answer your questions, and guide you through the process of joining the lawsuit. There is no cost or obligation to discuss your potential claim.

You May Be Entitled to Compensation

If you suffered financial losses as a result of purchasing Savara Inc. securities during the class period, you may be entitled to compensation. Completing the below form is the first step toward joining the lawsuit and seeking to recover your losses. Lawyers are ready to assist you every step of the way.

Sources

• Complaint
• Savara Inc.